• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Gemcitabine Injection 38 mg/mL

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

September 2013

Summary View

5 WARNINGS AND PRECAUTIONS 

5.9 Capillary Leak Syndrome
  • Capillary leak syndrome (CLS) with severe consequences has been reported in patients receiving gemcitabine as a  single agent or in combination with other chemotherapeutic agents. Discontinue gemcitabine if CLS develops during  therapy